Michelle E. Wolf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michelle E. Wolf has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Stefanie Arlene Sydlik
Department of Chemistry, Carnegie Mellon University, 4400 Fifth Avenue, Pittsburgh, PA, USA
6 shared publications - Karoline E. Eckhart
Department of Chemistry, Carnegie Mellon University, Pittsburgh, USA
4 shared publications - Francesca A. Starvaggi
Department of Chemistry, Stanford University, Stanford, CA 94305, USA
2 shared publications Jason D. Orlando
Department of Chemistry Carnegie Mellon University, Mellon Institute 4400 Fifth Ave Pittsburgh PA 15213 USA
2 shared publicationsStephen J. Schmidt
2 shared publications- Stephen J. Schmidt
Department of Chemistry, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, United States
2 shared publications
Latest Publications
- Open Access
- 21 May 2025
- Published by Wiley in ChemBioChem
- Vol. 26 (13) , e202500210
Covalent Peptide‐Graphene Conjugates for Enhanced Cell Spreading, Osteogenic Differentiation, and Angiogenesis in Bone Defects
Traumatic bone injury is one of the most common injuries that require surgical intervention, and current treatments suffer severe drawbacks. Modern research in bone regeneration focuses on implants that will support and enhance native tissue regeneration. One scaffold material that shows promise is graphene oxide (GO), a 2D nanomaterial made from oxidation of graphite. GO is biocompatible, strong, osteoinductive, is safely and slowly resorbed by the body, has a cheap, facile, and scalable synthesis, and is highly tailorable and functionalizable. The bioactivity of GO can be enhanced via functionalization with biomolecules such as peptides, proteins, and small molecules. Here, short peptides RGD, DGEA, and KKGHK are covalently bound to GO through a Claisen modification (CG) to create new functional graphenic materials that are cell‐adhesive, osteogenic, and angiogenic, respectively. These peptide‐Claisen graphenes (peptide‐CGs) are found to be cytocompatible, to encourage cell spreading on the graphenic surface, to promote osteogenesis in stem cells, and to induce angiogenesis in vascular endothelial cells. They show promise as next‐generation bone regeneration scaffolds by overcoming challenges frequently faced by bone regeneration scaffolds, namely retaining implanted and recruited cells, promoting their survival, proliferation, and differentiation, and ensuring a sufficient oxygen and nutrient supply to new tissue.
- 21 May 2025
- Published by Wiley in ChemBioChem
- Vol. 26 (13) , e202500210
Open AccessCovalent Peptide‐Graphene Conjugates for Enhanced Cell Spreading, Osteogenic Differentiation, and Angiogenesis in Bone Defects
Traumatic bone injury is one of the most common injuries that require surgical intervention, and current treatments suffer severe drawbacks. Modern research in bone regeneration focuses on implants that will support and enhance native tissue regeneration. One scaffold material that shows promise is graphene oxide (GO), a 2D nanomaterial made from oxidation of graphite. GO is biocompatible, strong, osteoinductive, is safely and slowly resorbed by the body, has a cheap, facile, and scalable synthesis, and is highly tailorable and functionalizable. The bioactivity of GO can be enhanced via functionalization with biomolecules such as peptides, proteins, and small molecules. Here, short peptides RGD, DGEA, and KKGHK are covalently bound to GO through a Claisen modification (CG) to create new functional graphenic materials that are cell‐adhesive, osteogenic, and angiogenic, respectively. These peptide‐Claisen graphenes (peptide‐CGs) are found to be cytocompatible, to encourage cell spreading on the graphenic surface, to promote osteogenesis in stem cells, and to induce angiogenesis in vascular endothelial cells. They show promise as next‐generation bone regeneration scaffolds by overcoming challenges frequently faced by bone regeneration scaffolds, namely retaining implanted and recruited cells, promoting their survival, proliferation, and differentiation, and ensuring a sufficient oxygen and nutrient supply to new tissue.
- Open Access
The Mitsunobu reaction for the gentle covalent attachment of biomolecules to graphene oxide
- Open Access
- 30 October 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (45)
Hyaluronic acid–British anti-Lewisite as a safer chelation therapy for the treatment of arthroplasty-related metallosis
Cobalt-containing alloys are useful for orthopedic applications due to their low volumetric wear rates, corrosion resistance, high mechanical strength, hardness, and fatigue resistance. Unfortunately, these prosthetics release significant levels of cobalt ions, which was only discovered after their widespread implantation into patients requiring hip replacements. These cobalt ions can result in local toxic effects—including peri-implant toxicity, aseptic loosening, and pseudotumor—as well as systemic toxic effects—including neurological, cardiovascular, and endocrine disorders. Failing metal-on-metal (MoM) implants usually necessitate painful, risky, and costly revision surgeries. To treat metallosis arising from failing MoM implants, a synovial fluid-mimicking chelator was designed to remove these metal ions. Hyaluronic acid (HA), the major chemical component of synovial fluid, was functionalized with British anti-Lewisite (BAL) to create a chelator (BAL-HA). BAL-HA effectively binds cobalt and rescues in vitro cell vitality (up to 370% of cells exposed to IC 50 levels of cobalt) and enhances the rate of clearance of cobalt in vivo ( t 1/2 from 48 h to 6 h). A metallosis model was also created to investigate our therapy. Results demonstrate that BAL-HA chelator system is biocompatible and capable of capturing significant amounts of cobalt ions from the hip joint within 30 min, with no risk of kidney failure. This chelation therapy has the potential to mitigate cobalt toxicity from failing MoM implants through noninvasive injections into the joint.
- 30 October 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (45)
Open AccessHyaluronic acid–British anti-Lewisite as a safer chelation therapy for the treatment of arthroplasty-related metallosis
Cobalt-containing alloys are useful for orthopedic applications due to their low volumetric wear rates, corrosion resistance, high mechanical strength, hardness, and fatigue resistance. Unfortunately, these prosthetics release significant levels of cobalt ions, which was only discovered after their widespread implantation into patients requiring hip replacements. These cobalt ions can result in local toxic effects—including peri-implant toxicity, aseptic loosening, and pseudotumor—as well as systemic toxic effects—including neurological, cardiovascular, and endocrine disorders. Failing metal-on-metal (MoM) implants usually necessitate painful, risky, and costly revision surgeries. To treat metallosis arising from failing MoM implants, a synovial fluid-mimicking chelator was designed to remove these metal ions. Hyaluronic acid (HA), the major chemical component of synovial fluid, was functionalized with British anti-Lewisite (BAL) to create a chelator (BAL-HA). BAL-HA effectively binds cobalt and rescues in vitro cell vitality (up to 370% of cells exposed to IC 50 levels of cobalt) and enhances the rate of clearance of cobalt in vivo ( t 1/2 from 48 h to 6 h). A metallosis model was also created to investigate our therapy. Results demonstrate that BAL-HA chelator system is biocompatible and capable of capturing significant amounts of cobalt ions from the hip joint within 30 min, with no risk of kidney failure. This chelation therapy has the potential to mitigate cobalt toxicity from failing MoM implants through noninvasive injections into the joint.
- Open Access
- 9 October 2023
- Published by Royal Society of Chemistry (RSC) in RSC Applied Polymers
- Vol. 2 (1) , 47-61
Aromatic polypeptide amphiphiles for drug adsorption: a new approach for drug overdose treatment
This work represents a new application of aromatic polypeptide amphiphiles as a gastrointestinal decontamination technology.
- 9 October 2023
- Published by Royal Society of Chemistry (RSC) in RSC Applied Polymers
- Vol. 2 (1) , 47-61
Open AccessAromatic polypeptide amphiphiles for drug adsorption: a new approach for drug overdose treatment
This work represents a new application of aromatic polypeptide amphiphiles as a gastrointestinal decontamination technology.
- 16 November 2022
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 5 (12) , 5608-5616
Hyaluronic Acid-Based Antibacterial Hydrogels for Use as Wound Dressings
Wound dressings have been shifting toward a more active role in the wound-healing process. Hydrated environments with additives to aid in the healing process are currently being explored through the application of hydrocolloid dressings. However, these moist healing environments are also ideal for bacterial growth, leading to the widespread use of antibiotics with concerns of antibiotic resistance and toxicity. To overcome this concern, we present a hydrogel wound dressing consisting of hyaluronic acid (HA) cross-linked with gentamicin. This hydrogel treats bacterial infection locally, lowering the effective dose and reducing the concerns of antibiotic resistance and systemic exposure. Changing the cross-linking density, by using varied amounts of a cross-linker, created gels that provided a sustained release of gentamicin for up to 9 days with a range of adhesive and cohesive properties. Overall, this HA hydrogel could provide an important solution in treating local infection in burns and other dermal injuries.
- 16 November 2022
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 5 (12) , 5608-5616
Hyaluronic Acid-Based Antibacterial Hydrogels for Use as Wound Dressings
Wound dressings have been shifting toward a more active role in the wound-healing process. Hydrated environments with additives to aid in the healing process are currently being explored through the application of hydrocolloid dressings. However, these moist healing environments are also ideal for bacterial growth, leading to the widespread use of antibiotics with concerns of antibiotic resistance and toxicity. To overcome this concern, we present a hydrogel wound dressing consisting of hyaluronic acid (HA) cross-linked with gentamicin. This hydrogel treats bacterial infection locally, lowering the effective dose and reducing the concerns of antibiotic resistance and systemic exposure. Changing the cross-linking density, by using varied amounts of a cross-linker, created gels that provided a sustained release of gentamicin for up to 9 days with a range of adhesive and cohesive properties. Overall, this HA hydrogel could provide an important solution in treating local infection in burns and other dermal injuries.
- 20 September 2021
- Published by American Chemical Society (ACS) in Journal of Chemical Education
- Vol. 98 (10) , 3153-3162
Hands-On Laboratory Experience Using Adhesives for Remote Learning of Polymer Chemistry
- 20 September 2021
- Published by American Chemical Society (ACS) in Journal of Chemical Education
- Vol. 98 (10) , 3153-3162
Hands-On Laboratory Experience Using Adhesives for Remote Learning of Polymer Chemistry
- 2 November 2020
- Published by Springer Nature in Regenerative Engineering and Translational Medicine
- Vol. 7 (4) , 460-484
Peptide- and Protein-Graphene Oxide Conjugate Materials for Controlling Mesenchymal Stem Cell Fate
- 2 November 2020
- Published by Springer Nature in Regenerative Engineering and Translational Medicine
- Vol. 7 (4) , 460-484
Peptide- and Protein-Graphene Oxide Conjugate Materials for Controlling Mesenchymal Stem Cell Fate